Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
August 20, 2001
- We Don't Want Reform That Profits Only Generic Makers: EMA President
August 20, 2001
- Sankyo, UAB Discover New Antibody with Tumoricidal Activity
August 20, 2001
- Reimbursement Prices to Be Set for 142 Medical Material Categories
August 20, 2001
- ACCJ White Paper Calls For Deregulations in Healthcare Services
August 20, 2001
- Bronchodilators Recommended for COPD: NBI Seminar
August 20, 2001
- Subcommittee Discusses Prices of Medical Materials
August 20, 2001
- Novo Nordisk: InnoLet, New Insulin Kit Targeted at the Elderly
August 20, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 20, 2001
- Fresenius to Supply Artificial Kidneys to Teijin
August 20, 2001
- Compounds under R&D by Japanese Makers in US Show Rapid Increases: JETRO Survey
August 20, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 20, 2001
- Canopus Develops New Image Distribution System for Hospitals
August 20, 2001
- BUSINESS NEWS IN BRIEF -1-
August 20, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2001
- BUSINESS NEWS IN BRIEF -2-
August 20, 2001
- Takara Launches 2 Additional DNA Chips
August 20, 2001
- Savings of \1.4 Trillion Possible by Reducing Drug Cost to 16%: Council Report
August 20, 2001
- Study on Diagnostic Method Using PALSAR Selected by JHSF
August 20, 2001
- 6th Designation for Quality Reevaluation Approved
August 20, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…